Literature DB >> 2826763

[3H]dihydroergotamine as a high-affinity, slowly dissociating radioligand for 5-HT1B binding sites in rat brain membranes: evidence for guanine nucleotide regulation of agonist affinity states.

M W Hamblin1, K Ariani, P I Adriaenssens, R D Ciaranello.   

Abstract

[3H]Dihydroergotamine (DE) labels a population of binding sites in rat brain membranes with an affinity of approximately 70 pM in both hippocampus (maximal binding at saturation [Bmax] = 340 fmol/mg of protein) and cerebral cortex (Bmax = 250 fmol/mg of protein). Specific binding typically comprises about 97% of total binding at the Kd of the radioligand when nonspecific binding is determined in the presence of 100 nM unlabeled DE. Association kinetics at 37 degrees C are consistent with a uniform association rate constant for all sites labeled. Specific binding is completely reversible with addition of excess unlabeled DE, but dissociation does not proceed with simple first-order kinetics, suggesting the presence of more than one discrete binding site. Competition studies with selective drugs reveal alpha adrenergic, 5-HT1A and 5-HT1B components of [3H]DE specific binding. When phentolamine (500 nM) is included to block alpha receptors and DPAT (100 nM) or spiroxatrine (500 nM) is included to block 5-HT1A receptors, specific binding is exclusively to sites with drug affinities characteristic of 5-HT1B receptors. Under these 5-HT1B-selective conditions, [3H]DE binding is about 90% specific, with a Kd of about 50 to 60 pM and a Bmax of 96 fmol/mg of protein in hippocampus and 77 fmol/mg of protein in cortex. [3H]DE binding to 5-HT1B sites is very slowly dissociable, with a T1/2 of greater than 2 h at 37 degrees C. 5-HT1B antagonists and DE itself yield competition curves at [3H]DE-labeled 5-HT1B sites that are adequately fit assuming a single site in nonlinear regression analysis. Competition by the agonists 5-HT and RU 24969 at 5-HT1B sites are often best described by two site fits. Addition of 100 microM guanylyl 5'-imidodiphosphate appears to convert nearly all 5-HT1B sites to those having low affinity for agonists while having a much smaller effect on the binding of [3H]DE. This suggests that the 5-HT1B site exists in two interconvertable agonist affinity states and is yet another member of the G-protein-linked receptor family. In agreement with previous studies using other radioligands, no 5-HT1B sites can be detected in bovine, porcine or human hippocampus membranes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2826763

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  Neurotransmitter enzyme and receptor regulation: a look back.

Authors:  R D Ciaranello
Journal:  Cell Mol Neurobiol       Date:  1988-03       Impact factor: 5.046

Review 2.  Pathophysiology of Migraine: A Disorder of Sensory Processing.

Authors:  Peter J Goadsby; Philip R Holland; Margarida Martins-Oliveira; Jan Hoffmann; Christoph Schankin; Simon Akerman
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

3.  G protein dependent alterations in [125I]iodocyanopindolol and +/- cyanopindolol binding at 5-HT1B binding sites in rat brain membranes.

Authors:  K Ariani; M W Hamblin; G L Tan; C A Stratford; R D Ciaranello
Journal:  Neurochem Res       Date:  1989-09       Impact factor: 3.996

4.  Possible antidepressant dihydroergosine preferentially binds to 5-HT1B receptor sites in the rat hippocampus.

Authors:  D Muck-Seler; D Pericić
Journal:  J Neural Transm Gen Sect       Date:  1993

5.  Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus.

Authors:  P Schoeffter; D Hoyer
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

6.  Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine.

Authors:  Christoph J Schankin; Farooq H Maniyar; Youngho Seo; Shashidar Kori; Michael Eller; Denise E Chou; Joseph Blecha; Stephanie T Murphy; Randall A Hawkins; Till Sprenger; Henry F VanBrocklin; Peter J Goadsby
Journal:  Brain       Date:  2016-05-27       Impact factor: 13.501

Review 7.  The 5-HT1B receptor - a potential target for antidepressant treatment.

Authors:  Mikael Tiger; Katarina Varnäs; Yoshiro Okubo; Johan Lundberg
Journal:  Psychopharmacology (Berl)       Date:  2018-03-15       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.